Between October 20, 2017 and February 20, 2018, the Vaccine Adverse Event Reporting System (VAERS) received 155 reports involving RZV, with 13 (8%) involving an administrative error.
CDC voted for Shingrix over Zostavax as herpes zoster vaccine of choice
More than 99% of immunocompetent persons aged 40 years and older have evidence of VZV infection and are susceptible to herpes zoster or shingles.
Risk of stroke and myocardial infarction may be more than double in the first week following a shingles diagnosis in elderly patients.
Stroke risk increased for three months immediately following a shingles diagnosis, with a two-fold risk during the first week.
Herpes zoster, more commonly known as shingles, may occur in anyone previously infected with chicken pox, but is most common in adults 60 years and older due to an age-related decline in immunity.
Patients with shingles who were not treated with antivirals had nearly twice the risk of stroke compared with those who received medication.
Immunocompetent older people who have had shingles recently have a relatively low short-term risk for developing the skin condition again, regardless of vaccination status, study data show.
The shingles vaccine is safe and well tolerated in older adults, despite a small increased risk for allergic reaction in the week following vaccination.
Gralise significantly improved patient's mean pain scores compared with placebo in an 11-week clinical trial.
An elderly patient presented with an acute reaction of shingles. How soon after treatment is it advisable to administer the zoster vaccine (Zostavax)?